

Review

'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations

Peadar G Noone and Michael R Knowles

Pulmonary Research and Treatment Center, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

Correspondence: Peadar G Noone, MD, Pulmonary Division, CB # 7248, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7248, USA. Tel: +1 919 966 1077; fax: +1 919 966 7524; e-mail: pnoone@med.unc.edu

Received: 18 June 2001

Respir Res 2001, **2**:328-332

Revisions requested: 25 June 2001

Revisions received: 29 June 2001

Accepted: 17 July 2001

© 2001 BioMed Central Ltd

Published: 9 August 2001

(Print ISSN 1465-9921; Online ISSN 1465-993X)

Abstract

Cystic fibrosis is a genetic disease that is associated with abnormal sweat electrolytes, sino-pulmonary disease, exocrine pancreatic insufficiency, and male infertility. Insights into genotype/phenotype relations have recently been gained in this disorder. The strongest relationship exists between 'severe' mutations in the gene that encodes the cystic fibrosis transmembrane regulator (CFTR) and pancreatic insufficiency. The relationship between 'mild' mutations, associated with residual CFTR function, and expression of disease is less precise. Atypical 'mild' mutations in the *CFTR* gene have been linked to late-onset pulmonary disease, congenital bilateral absence of the vas deferens, and idiopathic pancreatitis. Less commonly, sinusitis, allergic bronchopulmonary aspergillosis, and possibly even asthma may also be associated with mutations in the *CFTR* gene, but those syndromes predominantly reflect non-*CFTR* gene modifiers and environmental influences.

Keywords: asthma, cystic fibrosis (CF), cystic fibrosis transmembrane regulator (CFTR), mutations, pancreatitis, phenotype

Introduction

Cystic fibrosis (CF) is a recessive genetic disease that is caused by mutations on both *CFTR* alleles, resulting in abnormal sweat electrolytes, sino-pulmonary disease, male infertility, and pancreatic exocrine insufficiency in 95% of patients [1,2]. In its classic form, the disease is easily diagnosed early in life, through a combination of clinical evaluation and laboratory testing (including sweat testing, and *CFTR* mutation analysis) [3]. Depending on the ethnic background of the populations tested, common genetic mutations are identified in the majority of cases of CF. In the USA, two-thirds of patients carry at least one copy of the $\Delta F508$ mutation, with approximately 50% of CF patients being homozygous for this mutation [4].

A wide spectrum of molecular abnormalities may occur in the *CFTR* gene, and uncommon mutations that result in partial (residual) CFTR function may be associated with nonclassic presentations of disease. Overall, 7% of CF patients are not diagnosed until age 10 years, with a proportion not diagnosed until after age 15 years; some of these patients present a considerable challenge in establishing a diagnosis of CF. Moreover, the phenotype in these patients may vary widely [5,6]. The focus of the present review is on nonclassic phenotypes associated with mutations in the *CFTR* gene, which may manifest as male infertility (congenital bilateral absence of the vas deferens [CBAVD]), mild pulmonary disease and idiopathic chronic pancreatitis (ICP). These phenotypes are included within the definition of 'atypical CF'.

Table 1**Hierarchy of associations with mutations in the cystic fibrosis transmembrane regulator gene**

Phenotypes associated with <i>CFTR</i> mutations	Genetic/other influences		
	<i>CFTR</i>	Non- <i>CFTR</i> gene modifiers	Environment
'Atypical' CF*			
CBAVD	+++	+	+
Mild pulmonary disease	+++	+	+
ICP [†]	+++	+	+
Associated with mutations in <i>CFTR</i>[‡]			
Sinusitis	+	++	+
ABPA	+	++	+++
Asthma	+/- [§]	+++	++

*'Atypical' cystic fibrosis (CF) is associated with two mutations in *CFTR* (often one 'mild' and one 'severe'), together with *CFTR* dysfunction.

[†]Excluding other forms of genetic-linked idiopathic chronic pancreatitis (ICP). [‡]Associated with one mutation in *CFTR*, without *CFTR* dysfunction, but predominantly influenced by non-*CFTR* gene modifiers and nongenetic environmental factors. [§]Evidence for involvement with mutated *CFTR* is weak; other factors are mainly responsible for expression of disease. The number of '+' symbols indicates the strength of the association.

Cystic fibrosis transmembrane regulator: the relationship between gene mutations and function

CFTR is a transmembrane spanning protein with multiple activities that are related to normal epithelial cell function [2]. Mutations in *CFTR* result in abnormalities in epithelial ion and water transport, which are associated with derangements in airway mucociliary clearance and other cellular functions related to normal cell biology [7]. Depending on the molecular abnormality, the defect in *CFTR* may be the equivalent of that associated with a 'null' mutation, or may be 'mild', with partial/residual function [4]. At one end of the spectrum of severity, 'null' or 'severe' mutations reflect nonsense, frame-shift or splice mutations; these result in absence of production of functional *CFTR*, which correlates strongly with pancreatic exocrine insufficiency, but less strongly with severity of lung disease. At the other end of the spectrum, 'mild' mutations may result in some production of functional *CFTR* protein at the apical membrane, with partial *CFTR* channel function, and are generally associated with pancreatic sufficiency and milder pulmonary disease.

The molecular basis for the severity of mutations may derive from the extent to which normal mRNA transcription or protein synthesis takes place; for example, splice mutations may influence the efficiency of normal/abnormal *CFTR* mRNA transcription to varying degrees. In turn, the severity of the abnormality in *CFTR* may relate directly to the phenotypic expression of disease, with absent function causing more severe disease, whereas some residual function may modulate the severity of disease in different organ systems. Clinically, this may be reflected in normal or borderline sweat chloride values in patients with atypical CF.

Other factors, including non-*CFTR* gene modifiers and environmental influences, are probably also associated with the severity of disease. Given this background, it is not surprising that disease expression is complex and that nonclassic CF phenotypes exist.

Phenotypes associated with atypical cystic fibrosis

Table 1 provides a schema of how mutations on one or both alleles of the *CFTR* gene might relate to nonclassic phenotypic expression of disease. 'Atypical CF' includes those clinical phenotypes that have the strongest associations with mutations in the *CFTR* gene: CBAVD in males, mild pulmonary disease and ICP.

Congenital bilateral absence of the vas deferens

Although not all males with CBAVD have mutations in the *CFTR* gene, approximately 50% have abnormal *CFTR* alleles [8]. Generally, one 'severe' allele is combined with one 'mild' allele, such that the 'mild' allele appears to dominate and cause the milder phenotype (e.g. $\Delta F508$ in combination with R117H). Routine screening for common mutations that does not take into account milder or rarer mutations may miss many of the mild mutations associated with this particular clinical expression of disease [8]. This combination of mutations may occur in other forms of atypical CF (see below).

One particular abnormality deserves a special mention – the various alleles of the polythymidine tract in the intron 8 (IVS8) of the *CFTR* gene [9]. Of the three alleles that have been identified in IVS8 (5T, 7T and 9T), the 9T allele is associated with the most efficient usage of the intron 8 splice acceptor site. This efficiency decreases with shorter

polythymidine tracts (5T and 7T), which results in a lower than normal level of full-length *CFTR* mRNA and presumably in a decrease in mature, functional CFTR protein. For example, the mild *CFTR* mutation R117H is influenced by the polythymidine tract sequence, such that an R117H-bearing allele in *cis* with a 7T allele may result in CBAVD, whereas when R117H is associated with the 5T allele the phenotypic expression may be associated with atypical CF. R117H with a 9T allele may exhibit a normal phenotype. The 5T allele under the influence of other sequence variants in the *CFTR* gene may also be associated with atypical CF [10].

Although males with CBAVD may present to urology clinics, with no discernable lung or other organ presentation of disease, a careful work-up should be carried out to determine whether subtle lung disease is present. Evidence of CFTR dysfunction may be found on laboratory testing, with abnormal or borderline sweat chloride levels and/or abnormal CFTR-mediated chloride conductance in nasal epithelia [11,12]. Whether lung disease may develop later in life in these generally young males remains to be determined, but they should at least be counseled regarding lung health and cigarette smoking.

Mild pulmonary disease

Older patients with mild pulmonary disease, including bronchiectasis, may not present with symptoms until later in life, but are found to have atypical CF when appropriate investigations are carried out, including normal or borderline sweat chlorides and pancreatic sufficiency [10]. Thus, as with CBAVD, a careful work-up is mandatory. This should include not only a standard diagnostic work-up, including a sweat chloride and radiologic screening for subtle lung disease, but also nasal potential difference measures in order to evaluate CFTR at a physiologic level, and screening for mild and rare *CFTR* mutations [10]. A 'severe' mutation may be found on one allele, with a 'mild' mutation, such as the 5T abnormality (with or without other abnormalities in the *CFTR* gene), on the other allele. The level of expression of full-length mature CFTR may be less than that in CBAVD, with adverse consequences for the lung, albeit with a later presentation [10]. Although the pulmonary disease is milder than that with classic CF, these patients generally exhibit phenotypic similarities to CF; for example, the distribution of radiographic changes often involve the upper lobe, and mucoid *Pseudomonas aeruginosa* may be present in the lower airway.

Idiopathic bronchiectasis (IB) could loosely be defined as bronchiectasis in which no clear cause has been found, and in which the clinical pattern differs from CF and other known causes of bronchiectasis. Two studies [13,14] suggested that IB may be linked to mutated *CFTR*. In one study [13], five out of 16 patients with IB harbored the 5T allele in the *CFTR* gene. Of those, two were 5T/5T

homozygotes. Insufficient data were supplied regarding the clinical phenotype in the five patients harboring the 5T allele to draw any firm conclusions as to whether they would otherwise fulfill rigorous diagnostic criteria for CF [3]. In the second study [14], from France, 13 mutations were found in 16 *CFTR* alleles in 32 patients with idiopathic bronchiectasis. Only six of the 13 mutations were confirmed to be CF-causing mutations, with the remainder hypothesized as being 'potentially' CF causing. Four patients were compound heterozygotes, and all 11 of the patients who harbored mutations had abnormal sweat chloride levels (>60 mmol/l), with apparently no clear-cut evidence of CF otherwise ('isolated bronchiectasis'). Girodon *et al.* [14] speculated that IB might be related, at least in part, to mutated *CFTR*, with possible other factors at play. In any such population, atypical or variant CF is likely to be present in a proportion of patients studied in detail.

Idiopathic chronic pancreatitis

Recent reports [5,6,15,16] suggest that patients with an ICP phenotype have an increased incidence of mutations in *CFTR*. Such patients generally present with symptoms of pancreatitis at an older age than those patients with classic CF. Because CF carriers represent 3–4% of the general population, it is important to know whether one or two mutations predispose to ICP. Although the data initially appeared to suggest that patients with one mutation in *CFTR* were at risk, subsequent studies have borne out the observation of a link between mutated *CFTR* on both alleles and ICP.

A rigorous search was conducted for other mutations in patients with one *CFTR* mutation, and CFTR function in nasal epithelia was assessed *in vivo* in patients with ICP [17]. Sequencing of the *CFTR* gene indicated that nine out of 41 patients with ICP had two abnormal *CFTR* alleles; again the combination of 'severe' and 'mild', and having two mutations increased the risk for ICP 40-fold. ICP patients with two abnormal *CFTR* alleles had reduced CFTR-mediated chloride conductance in nasal epithelia as compared with ICP control individuals. The number of CFTR heterozygotes with ICP was no higher than is expected in the general population. These data strongly suggest that abnormalities on both alleles are required for expression of 'CF-related ICP', perhaps with some added influence from mutations in pancreatic inhibitor genes (*PRSS1*, *PSTI*) [18].

Other phenotypes associated with mutations in the cystic fibrosis transmembrane regulator gene

Other sino-pulmonary syndromes have been studied to test for a link to mutated *CFTR*; sinusitis, allergic bronchopulmonary aspergillosis, and asthma. However, the likelihood is that they predominantly reflect non-*CFTR* gene modifiers and environmental influences.

Sinusitis

In a recent study [19], DNA from 147 patients with chronic rhino-sinusitis was screened for 16 *CFTR* mutations, including the 5T sequence, and patients with a mutation had their DNA screened over the entire coding region. Eleven patients had a mutation in *CFTR* (all severe mutations, and one patient eventually developed CF), as compared with two out of 123 control individuals, whereas there was no difference in the incidence of the 5T allele between controls and study subjects. There was also a higher frequency of the M470V polymorphism on the opposite allele to that containing a severe mutation as compared with control individuals. Physiologic testing in the sinusitis patients showed normal indices of nasal epithelial sodium transport, with a slight reduction in *CFTR*-mediated chloride conductance. The authors of that report concluded that the combination of a severe mutation on one allele with a sequence variant that is not normally associated with CF on the opposite allele may be responsible. An analogy is again drawn with the other non-classic phenotypes, with enough residual *CFTR* function to protect against early, classic sino-pulmonary disease and a pancreatic phenotype, but clearly other non-*CFTR* factors may also be at play (Table 1).

Allergic bronchopulmonary aspergillosis

Although *Aspergillus fumigatus* is ubiquitous in nature, allergic bronchopulmonary aspergillosis (ABPA) occurs in only a small number of patients with asthma and CF; thus, genetic factors may play a role in the pathogenesis of ABPA in some patients. A study from several years ago [20] showed that, in a small number of patients who met criteria for ABPA, there was a higher frequency of abnormal *CFTR* alleles than expected. The authors of that report speculated that mutations in *CFTR* may play a role in the pathogenesis of ABPA, either as a result of heterozygosity alone (and 50% *CFTR* function), or heterozygosity plus other genetic factors that were not detected by the methods used in the study. The situation is probably similar to that in asthma, with genetic factors outside of *CFTR*, together with environmental influences, playing major roles.

Asthma

There are conflicting data as to whether mutations in the *CFTR* gene are over-represented in patients with asthma [21–23]. In Denmark, a questionnaire study was carried out in a cohort of carriers of the $\Delta F508$ mutation in *CFTR* [24]. Of 250 adults studied, it appeared that 9% reported symptoms of asthma, as compared with 6% of control non-carriers, with airways obstruction being present in those carriers with symptoms of asthma. However, there are clear limitations in a study of this kind, relying solely on a questionnaire for diagnosis. A second study investigated 144 patients with documented asthma [22], and identified 15 missense mutations in the *CFTR* gene of 15 patients, compared with none in a small control group. When tests were

carried out in a larger control group, however, the differences lost significance. In contrast, several other studies failed to show a link between mutations in *CFTR* and asthma, and if anything show a protective effect [23]. Thus, there is little evidence to support a link between asthma and abnormalities in *CFTR*, such that, if there is a link, then it plays a small role in the overall pathogenesis of disease, with a much larger role played both by genetic factors outside of *CFTR* and by environmental influences (Table 1).

Conclusion

Mutated *CFTR* may be associated with an atypical CF phenotype in the sino-pulmonary tract, pancreas, and male genital tract, with reduced *CFTR* epithelial function. Although abnormalities in the *CFTR* gene may play a minor role in the pathogenesis of asthma, sinusitis, and ABPA in subsets of patients, these diseases predominantly result from genetic (non-*CFTR*) and nongenetic environmental influences.

Acknowledgements

Work by the authors that is cited in the present review is supported by CFF L543, HL-04225, RR00046, and HL-34322.

References

1. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL: **Cystic fibrosis**. In *The Metabolic and Molecular Basis of Inherited Diseases*. 7th edn. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1996:3799-3876.
2. Stutts MJ, Boucher RC: **Cystic fibrosis gene and functions of CFTR**. In *Cystic Fibrosis in Adults*. Edited by Yankaskas JR, Knowles MR. Philadelphia: Lippincott-Raven Publishers; 1999:3-25.
3. Rosenstein BJ, Cutting GR, Boat TF, Cantin A, Dorkin HL, Durie P, FitzSimmons S, Knowles MR, Saiman L, Tullis E: **The diagnosis of cystic fibrosis: a consensus statement**. *J Pediatr* 1998, **132**:589-595.
4. Knowles MR, Friedman KJ, Silverman LM: **Genetics, diagnosis and clinical phenotype**. In: *Cystic Fibrosis in Adults*. Edited by Yankaskas JR, Knowles MR. Philadelphia: Lippincott-Raven; 1999:27-42.
5. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS: **Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis**. *N Engl J Med* 1998, **339**:653-658.
6. Sharer N, Schwarz M, Malone G, Howarth A, Painter J, Super M, Braganza J: **Mutations of the cystic fibrosis gene in patients with chronic pancreatitis**. *N Engl J Med* 1998, **339**:645-652.
7. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzky JT, Davis CW, Boucher RC: **Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease**. *Cell* 1998, **95**:1-20.
8. Mak V, Zielenski J, Tsui LC, Durie P, Zini A, Martin S, Longley TB, Jarvi KA: **Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia**. *JAMA* 1999, **281**:2217-2224.
9. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG: **Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA**. *Nat Genet* 1993, **3**:151-156.
10. Noone PG, Pue CA, Zhou Z, Friedman KJ, Wakeling EL, Ganesananthan M, Simon RH, Silverman LM, Knowles MR: **Lung disease associated with the IVS8 5T allele of the CFTR gene**. *Am J Respir Crit Care Med* 2000, **162**:1919-1924.
11. Osborne LR, Lynch M, Middleton PG, Alton EFWF, Geddes DM, Pryor JP, Hodson ME, Santis GK: **Nasal epithelial ion transport and genetic analysis of infertile men with congenital absence of the vas deferens**. *Hum Mol Genet* 1993, **2**:1605-1609.

12. Delmarco A, Pradal U, Cabrini G, Bonizzato A, Mastella G: **Nasal potential difference in cystic fibrosis patients presenting borderline sweat test.** *Eur Respir J* 1997, **10**:1145-1149.
13. Pignatti PF, Bombieri C, Benetazzo M, Casartelli A, Trabetti E, Gile LS, Martinati LC, Boner AL, Luisetti M: **CFTR gene variant ICS8-5T in disseminated bronchiectasis.** *Am J Hum Genet* 1996, **58**:889-892.
14. Girodon E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, Martin J, Lemay S, Scheid P, Housset B, Bignon J, Goossens M: **CFTR gene mutations in adults with disseminated bronchiectasis.** *Eur J Hum Genet* 1997, **5**:149-155.
15. Ockenga J, Stuhmann M, Ballmann M, Teich N, Keim V, Dork T, Manns MP: **Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis.** *Am J Gastroenterol* 2000, **95**:2061-2067.
16. Castellani C, Bonizzato A, Rolfini R, Frulloni L, Cavallini GC, Mastella G: **Increased prevalence of mutations of the cystic fibrosis gene in idiopathic chronic and recurrent pancreatitis.** *Am J Gastroenterol* 1999, **94**:1993-1995.
17. Noone PG, Zhou Z, Pace RG, Silverman LM, Knowles MR, Cohn JA: **Molecular, cell physiologic and clinical characteristics of patients with idiopathic pancreatitis with and without mutations in the CFTR gene [abstract].** *Pediatr Pulmonol* 1999, suppl **19**:A166.
18. Cohn JA, Bornstein JD, Jowell PS: **Cystic fibrosis mutations and genetic predisposition to idiopathic chronic pancreatitis.** *Med Clin North Am* 2000, **84**:621-631, ix.
19. Wang X, Moylan B, Leopold DA, Kim J, Rubenstein RC, Togias A, Proud D, Zeitlin PL, Cutting GR: **Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population.** *JAMA* 2000, **284**:1814-1819.
20. Miller PW, Hamosh A, Macek M Jr, Greenberger PA, MacLean J, Walden SM, Slavin RG, Cutting GR: **Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.** *Am J Hum Genet* 1996, **59**:45-51.
21. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG: **DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma.** *Lancet* 1998, **351**:1911-1913.
22. Lazaro C, de Cid R, Sunyer J, Soriano J, Gimenez J, Alvarez M, Casals T, Anto JM, Estivill X: **Missense mutations in the cystic fibrosis gene in adult patients with asthma.** *Hum Mutat* 1999, **14**:510-519.
23. Schroeder SA, Gaughan DM, Swift M: **Protection against bronchial asthma by CFTR DeltaF508 mutation: a heterozygote advantage in cystic fibrosis.** *Nat Med* 1995, **1**:703-705.
24. Swift M, Su Y: **DeltaF508 heterozygosity and asthma.** *Lancet* 1998, **352**:984-987.